Monomethyl Fumarate
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Venetoclax National Cancer Institute (NCI) | Phase 2/3 | B |
Evomela M.D. Anderson Cancer Center | Phase 2 | B |
FILGRASTIM M.D. Anderson Cancer Center | Phase 2 | B |
Fludarabine Patrick C. Johnson, MD | Phase 2 | B |
Humax-Cd20 M.D. Anderson Cancer Center | Phase 2 | B |
View all 16 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →